Eutectic Gallium-Indium Nanoparticles for Photodynamic Therapy of Pancreatic Cancer

Developing a cancer theranostic nanoplatform with diagnosis and treatment capabilities to effectively treat tumors and reduce side effects is of great significance. Herein, we present a drug delivery strategy for photosensitizers based on a new liquid metal nanoplatform that leverages the tumor microenvironment to achieve photodynamic therapeutic effects in pancreatic cancer. Eutectic gallium indium (EGaIn) nanoparticles were successfully conjugated with a water-soluble cancer targeting ligand, hyaluronic acid, and a photosensitizer, benzoporphyrin derivative, creating EGaIn nanoparticles (EGaPs) via a simple green sonication method. The prepared sphere-shaped EGaPs, with a core-shell structure, presented high biocompatibility and stability. EGaPs had greater cellular uptake, manifested targeting competence, and generated significantly higher intracellular ROS. Further, near-infrared light activation of EGaPs demonstrated their potential to effectively eliminate cancer cells due to their single oxygen generation capability. Finally, from in vivo studies, EGaPs caused tumor regression and resulted in 2.3-fold higher necrosis than the control, therefore making a good vehicle for photodynamic therapy. The overall results highlight that EGaPs provide a new way to assemble liquid metal nanomaterials with different ligands for enhanced cancer therapy.

Automated summary

The study presents a new liquid metal nanoplatform for cancer therapy, demonstrating high cellular uptake, targeting efficiency, and intracellular ROS generation of EGaPs. The near-infrared light activation of EGaPs showed potential to effectively eliminate cancer cells, making them a promising vehicle for photodynamic therapy. In vivo studies also showed tumor regression and higher necrosis compared to the control group, highlighting the potential of EGaPs for enhanced cancer therapy.